0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-66.12%PremiumMay 16, 2025Expiry Date9.76Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.52Leverage Ratio--Theta--Rho--Eff Leverage--Vega
uniQure NV Stock Discussion
Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Benzinga· 23 mins ago
Revolutionary Hemophilia B Treatment Eliminates Need for Regular Therapy in 94% of Patients
share your thoughts & ideas explain why 2025 will be amazing several break free and run
apextradez Wins so can you
No comment yet